|Day Low/High||178.05 / 180.91|
|52 Wk Low/High||147.60 / 270.63|
Sage Therapeutics, Incyte and Shire were among the biotech movers in premarket trading on Thursday.
The study tested the drug on patients aged 12 years and older for 26 weeks.
Latest Research Supports Greater Understanding of the Evolving Needs of Adults with ADHD
Natpar is the first and only licensed recombinant human parathyroid hormone therapy for chronic hypoparathyroidism
Shire launches campaign to raise global awareness during World PI Week
New drug launches and late stage trials will be under the microscope as eight European pharmaceuticals companies report Q1 earnings starting next week.
PatientsLikeMe and Shire plc (LSE: SHP, NASDAQ: SHPG) have announced a new collaboration that will support the development of a patient-centered, real world health learning system that expands understanding of...
The Dax rose following a strong performance from the automotive sector, but both London and Paris slumped.
Shire data presentations at AAAAI 2017 reinforce the efficacy, safety, and tolerability of CUVITRU for primary immunodeficiency patients
BioCryst's Hereditary angioedema drug-trial results not compelling.
Current drugs approved to prevent and reduce the frequency of HAE swelling attacks require injections, so BioCryst's once-daily pill has the potential to be more convenient.
Also up early Thursday: Bellicum and Novocure.
Shire posted full-year profits that were largely in-line with analysts' forecasts and said it could see double-digit percentage growth in 2017 earnings per share.